Co-Diagnostics, Inc. Invited to Speak on Coronavirus at Molecular Med Tri-Con in San Francisco
March 03 2020 - 6:30AM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of diagnostic tests and that recently reported it had
received a CE marking for its COVID-19 coronavirus assay, announced
today that it has been requested to speak at the 27th Annual
Molecular Medicine Tri-Conference, held March 1-4, 2020 in San
Francisco, California.
The Molecular Med Tri-Con is presented by the Cambridge
Healthtech Institute and regarded as the most comprehensive,
industry-leading event covering precision medicine and diagnostics
today. Following an introduction by Duncan MacCannell, CSO of the
Office of Advanced Molecular Detection, Centers for Disease Control
and Prevention, Company CEO Dwight Egan will deliver the
presentation, titled “COVID-19 Coronavirus Emergency Response Test
Development Utilizing Co-Diagnostics CoPrimer™ Technology,” on
March 3 at 11:10 am. The presentation comes less than a week after
cases of the novel coronavirus of unknown origin have been found in
California.
Mr. Egan remarked, “Following the first reported COVID-19 deaths
in the US and the Food and Drug Administration’s change in policy
to expedite availability of tests, discussing Co-Diagnostics’ role
in addressing the coronavirus epidemic with such a highly regarded
audience couldn’t be more timely. In the space of about a month,
our CoPrimer technology allowed us to design, develop, receive
regulatory approval for, and begin marketing detection tools to aid
in stemming the tide of this fast-spreading disease.
“We are honored to present our rapid response to this current
outbreak to the attendees at Tri-Con. Co-Diagnostics also feels
confident that this response is one that could be replicated
whenever needed, as we pursue our mandate of making molecular
diagnostic solutions accessible to all nations of the world, in
addition to quickly providing updated versions of our COVID-19 test
in the event of a mutation.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding the (i) use of
funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in certain verticals or markets, (iv)
capital resources and runway needed to advance the Company’s
products and markets, (v) increased sales in the near-term, (vi)
flexibility in managing the Company’s balance sheet, (vii)
anticipation of business expansion, and (viii) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200303005383/en/
Company Contact: Andrew Benson Head of Investor Relations
+1 801-438-1036 investors@codiagnostics.com Media Contact:
Jennifer Webb Coltrin & Associates, Inc +1.267.912.1173
jennifer_webb@coltrin.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024